according to standard literature and latest studies and reporting what is the pathogenesis of PXE
Reading File
Finding Sources
Searching PubMed
pseudoxanthoma elasticum pathogenesis ABCC6
Searching the Web
pseudoxanthoma elasticum PXE pathogenesis 2024 2025 ABCC6 ectopic mineralization mechanism
Reading File
Reading File
Reading Article
Reading Article
Reading File
Reading File
Reading File
Reading Web Page
PXE pathogenesis ABCC6 pyrophosphate mineralization mechanism elastic fiber
Finding Sources
Loading Image
Loading Image
I now have comprehensive information from multiple authoritative sources. Let me compile the complete answer.
Pathogenesis of Pseudoxanthoma Elasticum (PXE)
PXE (OMIM #264800) is an autosomal recessive multisystem connective tissue disease characterized by progressive ectopic mineralization and fragmentation of elastic fibers in the skin, Bruch's membrane of the eye, and the walls of midsized arteries. Understanding its pathogenesis requires integrating genetics, metabolic biochemistry, and tissue-level consequences.
1. Genetic Basis: ABCC6 Mutations
PXE is caused by biallelic loss-of-function mutations in the ABCC6 gene (chromosome 16p13.1), which encodes ATP-binding cassette sub-family C member 6 (ABCC6), also called multidrug resistance-associated protein 6 (MRP6). More than 300 pathogenic variants have been described (missense, nonsense, frameshift, large deletions). The most common in European populations is the p.Arg1141X nonsense mutation, accounting for ~30% of mutant alleles.
ABCC6 is an ATP-dependent transmembrane organic anion transporter expressed predominantly in the basolateral (sinusoidal) membrane of hepatocytes and to a lesser degree in renal proximal tubular cells. It is virtually absent from the affected target tissues — skin, eyes, and arteries — which is the key to understanding PXE as a metabolic (hepatic) disease rather than a primary connective tissue disorder.
(Andrews' Diseases of the Skin; Dermatology 2-Volume Set 5e, Fuster & Hurst's The Heart 15e)
2. The Central Metabolic Cascade: ABCC6 → ATP → PPi
This is the core molecular mechanism, now well-established from transplantation studies and parabiotic mouse models (Jiang et al., 2009–2010):
Step 1 — Hepatic ATP efflux
ABCC6 mediates the efflux of ATP across the basolateral membrane of hepatocytes into the portal sinusoidal circulation. This is the liver's primary contribution to systemic nucleotide pools.
Step 2 — ENPP1-mediated hydrolysis
The membrane-bound ectonucleotidase ENPP1 (ectonucleotide pyrophosphatase/phosphodiesterase 1) hydrolyzes extracellular ATP into AMP + inorganic pyrophosphate (PPi).
Step 3 — CD73 further metabolizes AMP → adenosine
CD73 (encoded by NT5E) converts AMP to adenosine, another anti-calcification molecule. This complete pathway (ABCC6 → ENPP1 → CD73 → TNAP) constitutes a purinergic signaling cascade that regulates mineralization inhibition.
Step 4 — PPi deficiency leads to unchecked mineralization
PPi is a potent inhibitor of hydroxyapatite crystal formation and precipitation onto organic matrices. In PXE patients, plasma PPi levels are significantly reduced (~50% of normal). Without adequate PPi, calcium phosphate deposits form preferentially on elastic fibers in connective tissues.
This explains the tissue selectivity: elastic fibers in skin dermis, Bruch's membrane, and arterial media have a particular propensity for calcium binding in the absence of PPi suppression.
(Kauffenstein G et al., Biology 2024, PMID 38392293; Jansen et al., PNAS 2013; Pfau K et al., Prog Retin Eye Res 2024, PMID 38815804)
3. The Purinergic Disease Concept (2024 Update)
The 2024 review by Kauffenstein, Martin & Le Saux reframes PXE as part of a "purinergic disease continuum" alongside:
| Disease | Gene | Pathway step affected |
|---|---|---|
| PXE | ABCC6 | ATP efflux from liver |
| GACI (Generalized Arterial Calcification of Infancy) | ENPP1 | ATP → PPi conversion |
| CALJA (Calcification of Joints and Arteries) | NT5E/CD73 | AMP → adenosine |
All three disorders share overlapping phenotypes and disrupt the same purinergic pathway at different points. PPi deficiency is the final common mechanism of ectopic mineralization in all three.
Beyond PPi, there are broad alterations in purinergic receptor signaling (P1 and P2 receptors), which may contribute to vascular tone dysregulation, inflammation, and platelet dysfunction in PXE.
4. Role of Other Mineralization Inhibitors
Matrix Gla Protein (MGP)
MGP is a potent local inhibitor of soft tissue calcification. It requires vitamin K-dependent γ-glutamyl carboxylation (mediated by GGCX) to become active. In PXE, there is secondary undercarboxylation of MGP in target tissues, contributing to reduced local mineralization inhibition. This is why warfarin (VKORC1 inhibitor → blocks vitamin K recycling → impairs MGP carboxylation) markedly accelerates ectopic mineralization in Abcc6−/− mice.
Clinical implication: Vitamin K antagonists should be avoided in PXE patients.
Fetuin-A
Fetuin-A (α2-Heremans-Schmid glycoprotein) is a serum glycoprotein that acts as a systemic "crystal inhibitor" by forming calciprotein particles. Reduced fetuin-A has been reported in PXE patients, potentially amplifying the pro-mineralization state.
Tissue-nonspecific alkaline phosphatase (TNAP)
TNAP hydrolyzes PPi → Pi (phosphate), so it promotes calcification by consuming PPi. Inhibition of TNAP in Abcc6−/− mice attenuates ectopic mineralization, making it a therapeutic target.
5. Role of the Bone Marrow and Immune System (Emerging Evidence, 2024)
A landmark 2024 study (PMC11260544) demonstrated that bone marrow–derived cells (particularly lymphocytes) also express ABCC6, and that restoring wild-type bone marrow in Abcc6−/− mice significantly reduces calcification. This suggests:
- The liver is not the sole source of circulating PPi-enabling activity
- The adaptive immune system and local inflammation (lymphangiogenesis was found in PXE skin) contribute substantially to the calcification process
- This opens a new mechanistic dimension beyond the "pure hepatic metabolic disease" model
6. Tissue-Level Pathology: Elastic Fiber Mineralization
Once plasma PPi is deficient and local inhibitors are insufficient, hydroxyapatite crystals preferentially nucleate on the mid-laminar elastic fibers in:
- Dermis (mid-portion) → yellow papules, "plucked chicken skin"
- Bruch's membrane (between RPE and choroid) → angioid streaks, peau d'orange, macular neovascularization
- Medial layer of midsized arteries → premature atherosclerosis, peripheral artery disease, renal hypertension
Histopathology: Elastic fibers appear fragmented, twisted, and curled ("raveled wool") on H&E; calcium stains (von Kossa, Alizarin red) highlight early deposits. The fibers stain gray-blue on H&E. Calcification is most severe in the mid-dermis.
7. PXE-Like Phenocopies
Several conditions mimic or share mechanisms with PXE:
- β-thalassemia / sickle cell disease: Secondary hemolysis promotes ABCC6 downregulation through iron overload and oxidative stress; PXE-like skin, vascular, and ocular lesions develop
- GGCX mutations: Loss of γ-glutamyl carboxylase → impaired MGP activation → PXE-like phenotype + coagulopathy
- Penicillamine use (Wilson disease): Drug-induced elastin cross-linking disruption → clinicohistologic PXE mimicry
Summary Schematic
ABCC6 mutations (liver)
↓
↓ Hepatic ATP efflux
↓
ENPP1 cannot generate adequate PPi
↓
↓ Plasma PPi + ↓ Carboxylated MGP + ↓ Fetuin-A
↓
Hydroxyapatite nucleation on elastic fibers
↓
Skin (dermis) → yellow papules, skin laxity
Eye (Bruch's membrane) → angioid streaks, CNV, blindness
Arteries (media) → premature atherosclerosis, hypertension, claudication
Key Recent Literature
| PMID | Study | Key Finding |
|---|---|---|
| 38815804 | Pfau et al., Prog Retin Eye Res 2024 | Comprehensive genetics–pathophysiology–clinical review; ocular focus |
| 38392293 | Kauffenstein et al., Biology 2024 | PXE as a "purinergic disease"; ABCC6→ENPP1→CD73→TNAP axis |
| 41519013 | Martin et al., Ann Dermatol Venereol 2026 | REACT-PXE consensus on diagnosis and future research |
| PMC11260544 | Bone marrow transplant study 2024 | Bone marrow ABCC6 contributes to PPi; adaptive immune system involvement |
Textbook sources: Andrews' Diseases of the Skin (9780323547536); Dermatology 2-Volume Set 5e (9780702082252); Fuster & Hurst's The Heart 15e (9781264257560); Emery's Elements of Medical Genetics and Genomics (9780702079665)
what is the metabolic hypothesis of PXE
Reading File
Finding Sources
Finding Sources
Searching PubMed
pseudoxanthoma elasticum metabolic disease hypothesis liver pyrophosphate
Searching the Web
PXE pseudoxanthoma elasticum "metabolic hypothesis" OR "metabolic disease" liver ABCC6 pyrophosphate parabiosis transplant evidence
Finding Sources
Searching PubMed
pseudoxanthoma elasticum metabolic disease liver transplant parabiosis Abcc6
Reading Web Page
metabolic hypothesis PXE liver ABCC6 pyrophosphate ectopic calcification mechanism evidence
Finding Sources
Searching PubMed
"pseudoxanthoma elasticum" metabolic ABCC6 pyrophosphate inhibitor
Reading Web Page
PXE metabolic disease liver ABCC6 hepatocyte transplant parabiosis PPi evidence
Reading File
Reading Article
I now have a thorough body of evidence from textbooks, the landmark Jiang 2009 paper, Germain 2017, the 2024 purinergic review, the 2025 JCI liver-heart crosstalk paper, and the liver transplantation case series. I can deliver a comprehensive, well-organized answer.
The Metabolic Hypothesis of PXE
The metabolic hypothesis (also called the inhibitor hypothesis or hepatic metabolic disease model) is the dominant framework explaining why mutations in a liver-expressed transporter (ABCC6) cause mineralization of distant tissues — the skin, eyes, and arteries — that express virtually no ABCC6 themselves. It arose to resolve a fundamental paradox and is supported by a convergence of genetic, experimental, clinical, and metabolomic evidence.
1. The Paradox That Generated the Hypothesis
When ABCC6 was identified as the PXE gene in 2000, it created an immediate puzzle. The affected tissues (mid-dermal elastic fibers, Bruch's membrane, arterial media) express little to no ABCC6, while the liver and kidneys — which are largely unaffected clinically — express it at very high levels. This was completely inconsistent with the prevailing model that PXE was a primary connective tissue disorder driven by a defective ECM protein in skin and vessels.
Two competing hypotheses emerged:
| Hypothesis | Core claim |
|---|---|
| "PXE cell" hypothesis | Target-tissue cells (fibroblasts, smooth muscle cells) produce a defective matrix that mineralizes intrinsically |
| Metabolic hypothesis | A circulating anti-mineralization factor, whose production depends on hepatic ABCC6, is deficient systemically — so normal target-tissue cells mineralize because the blood bathing them lacks a protective factor |
(Germain, Orphanet J Rare Dis 2017, PMID 28486967)
2. The Experimental Proof: Transplantation and Parabiosis Studies
Three landmark experiments directly tested these competing models using the Abcc6−/− mouse (which develops muzzle vibrissae calcification as an early biomarker):
Skin Grafting (Jiang et al., J Invest Dermatol 2009 — PMID 18685618)
- Muzzle skin from wild-type (WT) mice was grafted onto the back of Abcc6−/− (knockout, KO) mice
- The WT skin underwent mineralization in the KO host
- KO muzzle skin grafted onto WT mice did not mineralize in the WT systemic environment
Conclusion: Mineralization is driven by the systemic (circulating) environment, not intrinsic properties of the skin cells. A protective factor present in WT blood is absent in KO blood.
Hepatocyte Transplantation
- Engraftment of WT hepatocytes into Abcc6−/− mice produced up to 90% reduction in muzzle skin mineralization vs. untreated controls
- Liver-specific deletion of Abcc6 was sufficient to cause post-injury cardiac calcification, while heart-specific deletion was not
Conclusion: The liver is the critical source of the circulating protective factor. Restoring hepatic ABCC6 function corrects the systemic deficiency.
Parabiotic Pairing (Jiang et al., Am J Pathol 2010)
- WT mice surgically joined to Abcc6−/− mice (sharing a common circulation)
- Mineralization in KO mice was halted
Conclusion: A diffusible blood-borne factor from the WT mouse continuously suppresses mineralization in the KO partner.
Together, these three experiments firmly established that PXE is a metabolic disease of hepatic origin — the liver normally secretes something into the circulation that prevents elastic fiber calcification, and this factor is absent when ABCC6 is non-functional.
(Dermatology 2-Volume Set 5e, §ABC transporter defects: "PXE therefore actually represents a metabolic disorder with secondary connective tissue manifestations.")
3. Identification of the Circulating Factor: Inorganic Pyrophosphate (PPi)
The identity of the protective "factor" was solved by Jansen et al. (PNAS 2013):
ABCC6 → ATP efflux → ENPP1 → PPi + AMP
- ABCC6 on the basolateral membrane of hepatocytes mediates the efflux of ATP into the sinusoidal bloodstream
- The ectonucleotidase ENPP1 rapidly hydrolyzes extracellular ATP into AMP + inorganic pyrophosphate (PPi)
- PPi circulates as a potent inhibitor of hydroxyapatite crystal nucleation — it blocks calcium phosphate deposition onto organic matrices including elastic fibers
- In PXE, without hepatic ABCC6, ATP efflux is reduced → plasma PPi falls (~50% of normal) → mineralization goes unchecked
Supporting clinical evidence:
- Plasma PPi levels are measurably reduced in PXE patients
- ENPP1 mutations (GACI — Generalized Arterial Calcification of Infancy) cause a phenotypically overlapping disorder by disrupting the same pathway one step downstream
- Oral PPi supplementation reduces calcification in Abcc6−/− mice (Dedinszki et al., EMBO Mol Med 2017)
- Warfarin (which further impairs a secondary anti-mineralization pathway via vitamin K recycling and Matrix Gla Protein) dramatically accelerates mineralization in KO mice
4. The Complete Purinergic Pathway Model (2024)
The 2024 review by Kauffenstein, Martin & Le Saux (Biology, PMID 38392293) extended the metabolic hypothesis into a full purinergic disease framework:
Liver hepatocyte
↓ [ABCC6]
ATP efflux into portal circulation
↓ [ENPP1]
AMP + PPi ←— primary anti-mineralization factor
↓ [CD73 / NT5E]
Adenosine ←— secondary anti-mineralization molecule
↓ [TNAP] ←— consumes PPi (pro-calcification)
Pi (inorganic phosphate)
The Pi/PPi ratio in connective tissue fluids determines whether mineralization occurs. ABCC6 sits at the top of this cascade as the master upstream regulator.
Three diseases correspond to three steps in the same pathway:
| Gene mutated | Disease | Step affected |
|---|---|---|
| ABCC6 | PXE | ATP efflux from liver |
| ENPP1 | GACI | ATP → PPi conversion |
| NT5E | CALJA | AMP → adenosine |
5. Challenges and Evolution of the Hypothesis (2025 Update)
A 2025 JCI study (The liver regulates ectopic calcification in Abcc6-deficient models) reinforced the hepatic-metabolic model while adding important nuance:
- Tissue-specific Abcc6 deletion in the liver (but not in the heart) was sufficient to produce post-injury cardiac calcification
- Metabolomics and gene expression analysis showed deficiencies in nucleotide metabolism, cellular energetics, and mitochondrial respiration in affected tissues
- Evidence suggests ABCC6 may partly reside in mitochondria-associated ER membranes (MAMs), affecting mitochondrial function and lipid/calcium homeostasis
- Hepatic ABCC6 regulates mitochondrial function in distant organs through an altered systemic metabolic milieu — not only via PPi
The 2025 JCI data also explicitly notes that "pyrophosphate levels in individuals with PXE do not correlate well with the phenotype," suggesting PPi deficiency alone is not the complete explanation — broader metabolic disturbance (nucleotide pools, energy metabolism, mitochondrial function) contributes.
Additionally, bone marrow transplant studies (2024, PMC11260544) showed that bone marrow–derived lymphocytes also express ABCC6, and restoring WT bone marrow in KO mice reduces calcification — pointing to an inflammatory/immune contribution beyond pure hepatic metabolism.
6. Clinical Corroboration: Acquired PXE After Liver Transplantation
Three cases of acquired PXE developing after liver transplantation from ABCC6-mutant donors (without the recipient carrying ABCC6 mutations) have been reported (PMC3078966). This directly confirms:
- The disease can be transmitted through the liver (not through the skin or vessels)
- The liver is the driver of PXE pathology in humans, not just in mice
Summary: The Metabolic Hypothesis in One Paragraph
PXE is not a primary connective tissue disease. It is a hepatic metabolic disorder in which loss-of-function mutations in ABCC6 abolish the liver's normal efflux of ATP into the systemic circulation. The consequent failure of ENPP1-mediated PPi generation lowers plasma PPi to levels insufficient to inhibit hydroxyapatite nucleation on elastic fibers in skin, Bruch's membrane, and arterial walls. The target tissues themselves are intrinsically normal — they mineralize only because the blood supplying them lacks the protective circulating factor (PPi ± adenosine) that hepatic ABCC6 normally provides. Emerging 2024–2025 data further implicate liver-driven alterations in nucleotide metabolism, mitochondrial function, and immune activation as co-contributors, expanding the metabolic hypothesis beyond simple PPi deficiency into a broader model of systemic metabolic dysregulation.
Key sources:
- Jiang Q et al. J Invest Dermatol 2009 (PMID 18685618) — original skin graft proof
- Germain DP. Orphanet J Rare Dis 2017 (PMID 28486967) — comprehensive review
- Kauffenstein G et al. Biology 2024 (PMID 38392293) — purinergic pathway model
- Pfau K et al. Prog Retin Eye Res 2024 (PMID 38815804) — genetics/pathophysiology review
- Dermatology 2-Volume Set 5e (Bologniaet al.) — "PXE represents a metabolic disorder with secondary connective tissue manifestations"
- JCI 2025 — liver-heart crosstalk via mitochondrial metabolic milieu
PXE and skin
Reading File
Finding Sources
Finding Sources
Searching PubMed
pseudoxanthoma elasticum skin manifestations cutaneous lesions
Searching the Web
pseudoxanthoma elasticum skin manifestations cutaneous features histology 2024 2025
Reading File
Finding Sources
Reading Web Page
PXE skin cutaneous manifestations histology clinical features dermoscopy differential diagnosis
Reading File
Searching Images
pseudoxanthoma elasticum skin papules neck flexural histology calcified elastic fibers
Reading File
Loading Image
Loading Image
Reading File
Loading Image
I now have everything needed for a thorough, well-illustrated answer on PXE and the skin.
PXE and the Skin
The skin is the most consistently affected organ in PXE and typically the first to show clinical signs, often appearing in childhood or early adolescence. Cutaneous involvement represents the hallmark that gives the disease its name ("pseudo-xanthome élastique" — resembling xanthomas but of elastic origin).
1. Why the Skin Is Affected: The Tissue Basis
The dermis is rich in elastic fibers, particularly in the mid and deep layers. In PXE, circulating inorganic pyrophosphate (PPi) is chronically deficient (due to hepatic ABCC6 dysfunction), removing the physiologic brake on hydroxyapatite crystal formation. Elastic fibers in the mid-dermis are particularly vulnerable to calcium phosphate nucleation, and once mineralized, they progressively fragment and degenerate — a process called elastorrhexis.
2. Clinical Cutaneous Features
2a. Primary Lesions
The earliest and most characteristic lesion is small (1–5 mm), asymptomatic, yellowish or cream-colored papules arranged in a reticular pattern. These have been variably described as:
- "Plucked chicken skin" — the classic descriptor; the neck skin looks like the skin of a plucked bird
- "Cobblestone" appearance — as individual papules coalesce
- "Peau d'orange" texture — dimpled, orange-peel-like surface at a later stage
The lesions are non-pruritic, non-tender, and initially cosmetically subtle.
2b. Sites of Predilection
Cutaneous lesions are flexural and intertriginous — areas of repeated mechanical stress and folding where elastic fibers are most active:
| Site | Comment |
|---|---|
| Lateral neck | Most consistent, earliest, most visible |
| Axillae | Frequently involved |
| Antecubital and popliteal fossae | Classical flexural sites |
| Inguinal folds | Often affected |
| Periumbilical region | Distinctive involvement |
| Periauricular skin | Commonly overlooked |
| Mental creases (chin) | Horizontal chin creases before age 30 are highly suggestive of PXE |
| Nasolabial folds | Characteristically exaggerated |
2c. Progressive Changes
Over time, the papules coalesce into larger plaques with redundant, lax, wrinkled skin folds. Affected skin becomes:
- Lax and pendulous — due to loss of elastic fiber structural integrity
- Thickened and leathery — especially in advanced disease
- Redundant skin folds — most prominent on the lateral neck and axillae
This skin laxity progresses independently of the patient's age and is not simply due to aging.
2d. Mucosal Involvement
PXE is not confined to the skin surface. Mucous membranes may show involvement of the:
- Soft palate
- Inner lip
- Tonsils
- Stomach, rectum, and vagina (detected on endoscopy/biopsy)
This mucosal involvement is clinically relevant because gastric mucosal PXE underlies the risk of gastrointestinal hemorrhage.
2e. Nuchal Comedones and Milia en Plaque
Nuchal (nape-of-neck) comedones and milia en plaque may occur in the same flexural areas and are described in Andrews' Diseases of the Skin as associated findings.
3. Histopathology of the Skin
Histopathological examination of an affected skin biopsy is essential for definitive diagnosis and reveals the following:
3a. Primary Findings (Light Microscopy)
| Feature | Detail |
|---|---|
| Elastorrhexis | Fragmented, short, twisted, curled elastic fibers — the primary histological hallmark |
| Calcified elastic fibers | Mid-to-deep dermis; calcium deposits on the elastic fibers ("mineralized elastin") |
| H&E staining | Elastic fibers appear gray-blue, twisted and broken — described as "raveled wool" |
| Distribution | Mid and lower dermis; the upper (papillary) dermis is typically spared |
| Collagen fibers | Collagen flowers (abnormal fibrils) and increased proteoglycans may be seen adjacent to mineralized fibers |
3b. Special Stains
| Stain | Result / Use |
|---|---|
| Von Kossa | Black deposits — confirms calcium (most sensitive for early disease) |
| Alizarin red | Red/orange deposits — calcium |
| Verhoeff–van Gieson (VVG) | Highlights elastic fiber fragmentation |
| Calcium stains | Helpful for early/subclinical disease in normal-appearing skin |
3c. Ultrastructure (Electron Microscopy)
- Elastic fibers show pleomorphic mineralized deposits within the amorphous elastin core and along microfibrils
- Calcium crystals (hydroxyapatite) are oriented along the long axis of fibers
- Fibroblasts are hypertrophied with prominent rough ER (suggesting reactive synthetic activity)
- Macrophages are abundant within calcified deposits (phagocytosing mineral)
- Ultrastructural elastic fiber degeneration can be found in clinically non-lesional skin — important for early/blind biopsies
4. Diagnostic Significance of the Skin
Skin as Diagnostic Gateway
The 2014 Revised Diagnostic Criteria for PXE (Bolognini et al., incorporated in Dermatology 5e, Table 97.5) elevate skin findings to major criteria:
Definite PXE requires:
- Both major skin criteria plus one major eye criterion, or
- Major genetic criterion (biallelic pathogenic ABCC6 variants)
Major skin criteria:
- Characteristic pseudoxanthomatous papules and plaques on the neck and/or flexural sites
- Histopathologic evidence of calcified elastic fibers in the mid and lower dermis of affected skin
Diagnostic Biopsy Pearls
- Blind biopsies of old scars or axillary skin in patients with a family history or angioid streaks may reveal early PXE changes even without clinical skin lesions
- Non-lesional skin biopsy showing histopathologic PXE changes = minor criterion
- Mental creases before age 30 are highly suggestive and should prompt biopsy
5. PXE-Like Skin Conditions: Differential Diagnosis
Several conditions can mimic PXE clinically and/or histologically:
| Condition | Distinguishing features |
|---|---|
| PXE-like papillary dermal elastolysis | Cobblestone yellow papules on neck; NO retinal/vascular disease; NO calcification on histology |
| Elastosis perforans serpiginosa | Red serpiginous/annular papules; transepidermal elimination of elastic material |
| Cutis laxa | Skin laxity without papules; elastic fibers reduced not calcified |
| Connective tissue nevus with elastorrhexis | Small white papules, upper chest/neck; no systemic findings |
| Perforating calcific elastosis (Kyrle's) | Periumbilical in multiparous, obese women; associated with chronic renal disease |
| D-penicillamine–induced PXE-like changes | Drug history (Wilson's, homocystinuria); NO calcification; lesions may resolve after stopping drug |
| β-thalassemia / sickle cell disease | Up to 20% develop PXE-like skin; no ABCC6 mutation; due to downregulation of ABCC6 expression in liver |
| GGCX mutations | PXE-like skin + vitamin K-dependent coagulation factor deficiency |
| Amyloid elastosis | Amyloid deposits encasing dermal elastic fibers; in setting of primary systemic amyloidosis |
| Acanthosis nigricans | Brown velvety plaques; different morphology; metabolic/insulin association |
Key rule: No calcification on histology → most likely NOT true PXE. No retinal/vascular findings with only skin changes → consider PXE-like papillary dermal elastolysis.
6. Skin as Biomarker and Clinical Signpost
Although the skin lesions in PXE are primarily a cosmetic concern, they carry important systemic implications:
- Their presence signals ongoing elastic fiber calcification throughout the body
- Severity of skin involvement does not reliably predict ocular or cardiovascular severity (significant intrafamilial variability even among siblings)
- Appearance of mental creases or nuchal skin changes in a young person (<30 years) should trigger ophthalmologic assessment and cardiovascular screening
- Gastric involvement (mucosa) explains the ~10% risk of gastric hemorrhage
7. Treatment of Skin Manifestations
No definitive treatment reverses established cutaneous PXE. Current management is:
- Cosmetic/surgical: Plastic surgery for redundant skin folds (particularly neck and axillary) in severe cases
- Dietary: Limiting dietary calcium and phosphorus to the minimum daily requirement — some evidence of benefit
- Emerging systemic therapies targeting the underlying mineralization (PPi analogues/etidronate, TNAP inhibitors, recombinant ENPP1, magnesium supplementation, inositol, sodium thiosulfate) may indirectly slow cutaneous progression
- A randomized controlled trial of etidronate (a PPi analogue) showed it may halt progression of arterial calcification; data on skin is less established
Sources:
- Dermatology 2-Volume Set 5e (Bolognini et al.) — Ch. 97, §§ Clinical Features, Pathogenesis, Diagnostic Criteria, Differential Diagnosis
- Andrews' Diseases of the Skin — Ch. 25, PXE
- Boraldi F et al. Int J Mol Sci 2015 — "PXE and skin: Clinical manifestations, histopathology, pathomechanism, perspectives of treatment" (PMID 26361562)
- Cleveland Clinic Journal of Medicine 2026 — cobblestone appearance, bramble-bush histology
give some pictures of the cosmetic plastic surgery, target ectopic mineralization, etidronate, TNAP inhibitors, recombinant ENPP1, Magnesium, sodium thiosulfate, inositol
Reading File
Your credits are exhausted. Your daily credits reset tomorrow, or you can purchase a top-up for more.
This is a shared conversation. Sign in to Orris to start your own chat.